Page last updated: 2024-10-27

flutamide and Heart Diseases

flutamide has been researched along with Heart Diseases in 1 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bolla, M1
de Reijke, TM1
Van Tienhoven, G1
Van den Bergh, AC1
Oddens, J1
Poortmans, PM1
Gez, E1
Kil, P1
Akdas, A1
Soete, G1
Kariakine, O1
van der Steen-Banasik, EM1
Musat, E1
PiƩrart, M1
Mauer, ME1
Collette, L1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation[NCT02460549]9 participants (Actual)Interventional2014-04-30Completed
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707]Phase 2/Phase 312 participants (Actual)Interventional2013-12-31Terminated (stopped due to enrollment default)
A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma[NCT01040624]77 participants (Actual)Interventional2009-12-31Completed
Long Term Adjuvant Hormonal Treatment With LHRH Analogue Versus No Further Treatment in Locally Advanced Prostatic Carcinoma Treated by External Irradiation and a Six Months Combined Androgen Blockade - A Phase III Study[NCT00003026]Phase 3966 participants (Anticipated)Interventional1997-04-30Completed
A Phase II Study of Dose-Escalated Proton-Based Radiation Therapy Delivered With a Simultaneous Integrated Boost (SIB) to Intraprostatic Tumors (IPT) Visible on Pretreatment Magnetic Resonance Image[NCT03624660]100 participants (Anticipated)Interventional2018-09-24Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Acute Grade 3 or Higher Treatment-related Toxicity Rate.

Number of participants that experienced acute grade 3 or higher, treatment-related toxicity based on CTCAE version 3.0 criteria. (NCT01040624)
Timeframe: 6 months after the completion of radiation therapy

Interventionparticipants (Number)
HR-A1
HR-B3

Trials

1 trial available for flutamide and Heart Diseases

ArticleYear
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009
Duration of androgen suppression in the treatment of prostate cancer.
    The New England journal of medicine, 2009, Jun-11, Volume: 360, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F

2009